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Purpose: We investigated correlations of coronary plaque composition deter-
mined by virtual histology (VH) intravascular ultrasound (IVUS) and blood levels 
of biomarkers that represent the vulnerability of coronary plaques. Materials and 
Methods: Pre- and postprocedural blood levels of high sensitivity C-reactive pro-
tein, soluble CD40 ligand (sCD40L), matrix metalloproteinase-9, and neopterin 
were measured in 70 patients with stable angina (SA) or unstable angina (UA) 
who were undergoing percutaneous coronary intervention (PCI) for single lesions. 
We evaluated the data for correlations between these biomarkers and necrotic core 
contents in PCI target lesions analyzed by VH. Results: Clinical characteristics, 
IVUS, VH, and biomarker blood levels were not different between the SA and the 
UA group except for more frequent previous statin use (52.3% vs. 23.1%, p=0.017) 
and lower remodeling index in the SA group (0.98±0.09 vs. 1.10±0.070, p<0.001). 
Among the biomarkers evaluated, only pre-PCI neopterin level showed a weakly 
significant correlation with the absolute volume of the necrotic core (r=0.320, 
p=0.008). Pre- and post-PCI blood levels of sCD40L (r=0.220, p=0.072; r=0.231, 
p=0.062) and post-PCI blood level of neopterin (r=0.238, p=0.051) showed trends 
toward weakly positive correlations with the absolute volume of necrotic core. 
Conclusion: We found a weakly positive correlation between the pre-PCI neopter-
in level and necrotic core volume in the PCI-target lesion. The clinical implications 
of our findings need to be investigated in further studies.
Key Words:    Atherosclerosis, coronary artery disease, inflammation, intravascular 
ultrasound
INTRODUCTION
The process of coronary plaque destabilization, rupture, and thrombosis is associ-
ated with the development of acute coronary syndrome (ACS).1 Vulnerable athero-
sclerotic plaques are prone to rupture and are generally characterized by a large 
lipid core, the presence of inflammatory cells, a paucity of smooth muscle cells Necrotic Core by VH and Biomarkers 
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2-stent technique, chronic total occlusion, restenotic lesion, 
all women with childbearing potential or women with preg-
nancy, known bleeding diathesis or bleeding history within 
the previous 3 months, and contraindications to antiplatelet 
agents. We also excluded patients with acute myocardial in-
farction because in these patients the blood levels of bio-
markers might be influenced not only by the vulnerability 
of coronary plaques but also by the extent of myocardial 
necrosis. In addition, we excluded patients who took corti-
costeroids or other anti-inflammatory drugs except low-
dose aspirin, and patients with any identifiable condition 
that was related to infectious, active allergic, connective tis-
sue-related, or other chronic inflammatory diseases febrile 
conditions, acute infection, or known chronic inflammatory 
disease. Informed written consent was obtained from all pa-
tients, and the study protocol was approved by the institu-
tional review board of Yonsei University Health System in 
accordance with the Declaration of Helsinki.
SA was defined as no change in the frequency, duration, 
or intensity of symptoms within 6 weeks before the inter-
vention. UA was defined as chest pain occurring at rest and 
lasting longer than 20 min, new-onset chest pain of at least 
Canadian Cardiovascular Society class III severity, or pre-
viously diagnosed angina that has become distinctly more 
frequent, longer in duration, or lower in threshold. 
Percutaneous coronary intervention
All patients were placed on chronic aspirin (100-325 mg/
day) and clopidogrel (75 mg/day) therapy for ≥5 days or re-
ceived aspirin (250 mg) and clopidogrel (300-600 mg) 
loading at least 12 hours before PCI. Unfractionated hepa-
rin was administered according to the local standards of 
care (target activated clotting time >250 sec) at a dosage 
consonant with label instructions. In all patients, PCI target 
lesions were predilated prior to stenting and treated with 
drug-eluting stents such as a zotarolimus-eluting stent (En-
deavor Sprint® or Endeavor Resolute®, Medtronic Vascular 
Inc., Santa Rosa, CA, USA), sirolimus-eluting stent (Cy-
pher®, Cordis, Johnson & Johnson, Miami Lakes, FL, 
USA) or everolimus-eluting stent (Xience V®, Abbott Vas-
cular, Santa Clara, CA, USA). After implantation of the 
stent, aspirin (100 mg/day) was administered indefinitely, 
and clopidogrel (75 mg/day) was given for 3 or 12 months 
according to the RESET study protocol.
Intravascular ultrasound and virtual histology  
IVUS investigations were performed in all PCI target le-
and fibrous tissue, thinning of the fibrous cap, positive re-
modeling, and intimal neovascularization.1-3 Various mole-
cules of inflammation and tissue proteolysis are activated in 
the formation of vulnerable plaques.4-6 C-reactive protein 
(CRP), soluble CD40 ligand (sCD40L), matrix metallopro-
teinase (MMP), and neopterin are known to be involved in 
the process, and their blood levels are elevated in patients 
with ACS.7-11 
Virtual histology (VH) of intravascular ultrasounds (IVUS) 
(Volcano Therapeutics, Inc., Rancho Cordova, CA, USA) 
was developed to assess the tissue compositions of coronary 
plaques. VH uses spectral analysis of radiofrequency ultra-
sound signals and classifies plaques into four major compo-
nents: fibrous, fibro-fatty, necrotic core, and dense calci-
um.12,13 Previous studies found that culprit lesions in patients 
with ACS have greater amounts of necrotic core than with 
target lesions in patients with stable angina (SA), and that ne-
crotic core volume predicts microembolism and no reflow 
during percutaneous coronary intervention (PCI).14-16
Therefore, the purpose of the present study was to inves-
tigate whether the relative content of necrotic core, deter-
mined by VH, is correlated with periprocedural blood lev-
els of various biomarkers that represent the vulnerability of 
coronary plaques in patients undergoing PCI.
MATERIALS AND METHODS
　　　
Patients
A total of 70 consecutive patients with SA or unstable angi-
na (UA), participating in the Real Safety and Efficacy of a 
3-month Dual Antiplatelet Therapy Following Zotarolimus-
eluting Stents Implantation (RESET) trial who underwent 
PCI at Severance Cardiovascular Hospital, Yonsei Univer-
sity Health System, Seoul, Korea, were enrolled in this study. 
Inclusion criteria were age >20 years, the presence of a sin-
gle significant coronary artery stenosis (>50%) with a clini-
cal presentation of stable or unstable angina, and the pres-
ence of a PCI target lesion with a reference diameter of 2.5-
4 mm and a lesion length ≤26 mm that could be covered by 
a single stent. Exclusion criteria were hemodynamic insta-
bility, heart failure (left ventricular ejection fraction <40%), 
history of stroke, peripheral artery disease, significant he-
patic (aspartate aminotransferase or alanine aminotransfer-
ase ≥3 times the upper limit of normal range) or renal fail-
ure (serum creatinine >2.0 mg/dL), previous use of drug-
eluting stents, left main disease, bifurcation lesion requiring Young-Guk Ko, et al.
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pressed as mean±SD. Continuous variables were analyzed 
using unpaired t-tests and the Mann-Whitney U-test, as ap-
propriate. Categorical data and proportions were analyzed 
using the χ2-test or Fisher’s exact test, as required. Pearson’s 
two-way test was used to assess the relationships between 
two quantitative variables with normal distributions. For all 
tests, two-tailed p values <0.05 were considered significant.
 
RESULTS
 
Baseline clinical characteristics 
Among the 70 enrolled patients (age 60.4±8.9 years, male 
57.1%), there were 26 UA and 44 SA patients. There were 
no significant differences between the two patient groups in 
baseline characteristics such as age, gender, diabetes melli-
tus, hypertension, hypercholesterolemia, current smoking, 
renal failure, previous stroke, and multivessel disease (Ta-
ble 1). However, the SA group had a higher frequency of 
previous statin use (52.3% vs. 23.1%, p=0.017). Conse-
quently, total cholesterol (170.4±37.7 vs. 194.6±38.2 mg/
dL, p=0.013) and low density lipoprotein cholesterol levels 
(95.5±34.1 vs. 114.9±37.4 mg/dL, p=0.032) were lower in 
the SA group than in the UA group.   
Angiographic characteristics and procedural data
Angiographic characteristics and procedural data did not 
differ significantly between the UA and SA patient groups 
and are summarized in Table 2. The most common target 
lesion location was the left anterior descending artery. The 
majority of the lesions were type B2 or C lesions according 
to the American College of Cardiology/American Heart As-
sociation classification. All lesions were successfully treat-
ed with a single drug-eluting stent. 
 
IVUS and virtual histology data
Preprocedural IVUS and VH data are presented in Table 3. 
There were no significant differences in vessel, lumen, and 
P&M area at the target lesion cross section with the mini-
mum lumen area or in the vessel, lumen, and P&M volume 
of the target lesion between the SA and UA patient groups. 
VH also demonstrated no significant intergroup differences 
in plaque composition at the target lesion cross section with 
minimum lumen area or in the tissue component of the whole 
target lesion. However, patients with UA showed a trend to-
ward greater necrotic volume (9.4±3.8% vs. 7.5±3.7%, 
p=0.052) and less fibro-fatty tissue (15.1±8.1% vs. 18.3± 
sions prior to predilation using a 20-MHz 2.9F, phased-array 
IVUS catheter (Eagle Eye, Volcano Therapeutics, Rancho 
Cordova, CA, USA). After intracoronary administration of 
nitroglycerin (200 μg), the IVUS catheter was placed distal 
to the target lesion and then pulled back using a motorized 
pullback system at 0.5 cm/s. During pullback, gray-scale 
IVUS was recorded and raw radiofrequency data were cap-
tured at the top of the R wave for reconstruction of the col-
or-coded map by a VH-IVUS data recorder (Volcano Ther-
apeutics). Gray-scale quantitative IVUS analyses of external 
elastic membrane, lumen, plaque, and media (P&M, exter-
nal elastic membrane-lumen) were performed according to 
the Clinical Expert Consensus Document on IVUS.17 The re-
modeling index for the PCI target lesion was defined as the 
ratio of the external elastic membrane (EEM) area at the 
cross-section with minimum luminal area to the reference 
EEM area (average of the proximal and distal reference seg-
ments). VH data were analyzed for the site of the minimal lu-
men area and the whole length of the target lesion at 1-mm 
intervals using pcVH software (Volcano Therapeutics). VH 
analysis coded tissue as green (fibrotic), yellow-green (fibro-
fatty), white (dense calcium), or red (necrotic core).12,13 VH 
analyses were reported in absolute amounts and as percent-
ages (relative amounts) of plaque area or volume. 
 
Laboratory assessment
Blood samples were obtained before bolus administration of 
heparin and PCI in the catheterization room and 24 h after 
PCI. The blood samples were centrifuged immediately, and 
both plasma and serum were aliquoted and stored at -80°C 
for subsequent analysis. Investigational biomarkers, includ-
ing high sensitivity CRP (hsCRP), MMP-9, sCD40L, and 
neopterin, were measured at an external clinical laboratory 
(Seoul Clinical Laboratories, Seoul, Korea). Serum hsCRP 
was measured using a latex-enhanced turbidimetric immu-
noassay. The serum levels of MMP-9 and plasma levels of 
sCD40L and neopterin were determined using Quantikine® 
immunoassays (R&D Systems, Minneapolis, MN, USA), 
which use a quantitative sandwich enzyme immunoassay 
technique.
Statistical analysis
All analyses were performed using SPSS version 18.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Categorical 
variables were expressed as percentages and compared us-
ing chi-square tests. When the expected cell number was <5, 
Fisher’s exact tests were used. Continuous data were ex-Necrotic Core by VH and Biomarkers 
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in pre- and postprocedural blood levels of these biomarkers. 
However, there was a significant intergroup difference in 
blood sCD40L levels observed before and after the procedure. 
The UA patient group showed a significantly greater increase 
in the sCD40L level than the SA group (2.9 ±0.8 vs. -0.1±0.3 
ng/mL, p=0.043). Table 5 shows the correlations between 
the necrotic core content in the target lesion and the bio-
marker blood levels. Among the biomarkers evaluated, 
7.6%, p=0.110) than SA patients. The remodeling index 
was significantly greater for the UA group than the SA 
group (1.10±0.070 vs. 0.98±0.09, p<0.001).  
Blood levels of biomarkers
Pre- and postprocedural blood levels of hsCRP, sCD40L, 
MMP-9, and neopterin are shown in Table 4. Between the SA 
and UA patient groups, there were no significant differences 
Table 1. Baseline Clinical Characteristics 
Stable angina (n=44) Unstable angina  (n=26) p value
Age, yrs 61.1±8.2 59.2±9.9 0.381
Male 26 (59.1%) 14 (73.6%) 0.668
Diabetes mellitus   5 (11.4%)   4 (15.4%) 0.718
Hypertension 25 (56.8%) 14 (53.8%) 0.809
Hypercholesterolemia 34 (77.3%) 16 (61.5%) 0.159
Current smoker   9 (20.5%)   8 (30.8%) 0.598
Renal failure 1 (2.3%) 1 (3.8%) 0.703
Stroke 1 (2.3%) 0 (0%) 0.999
Multivessel disease   6 (13.7%)   6 (23.0%) 0.599
Total cholesterol 170.4±37.7 194.6±38.2 0.013
LDL-cholesterol   95.5±34.1 114.9±37.4 0.032
HDL-cholesterol 46.3±9.6   48.3±16.7 0.545
Triglyceride 143.6±81.4 158.8±80.9 0.456
Previous medication 
    Aspirin 14 (31.8%)   4 (15.4%) 0.163
    Statin 23 (52.3%)   6 (23.1%) 0.017
    ACEI/ARB   8 (33.3%)   3 (25.0%) 0.609
LDL, low density lipoprotein; HDL, high density lipoprotein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 2. Angiographic Characteristics and Procedural Data 
Stable angina (n=44) Unstable angina (n=26) p value
Target vessel  0.507
    LAD 36 (81.8%) 19 (73.1%)
    LCX 3 (6.8%)   4 (15.4%)
    RCA   5 (11.4%)   3 (11.5%)
B2/C lesion 33 (76.7%) 17 (65.4%) 0.306
Lesion length, mm 15.0±4.8 14.0±3.9 0.354
Reference diameter, mm   3.2±0.4   3.3±0.4 0.273
Minimum lumen diameter, mm    1.2±0.4   1.3±0.6 0.209
Diameter stenosis, %   64.2±12.6   61.0±14.3 0.328
Post-stent luminal diameter, mm   3.0±0.4   3.1±0.4 0.275
Post-stent residual stenosis, %   9.8±7.1   7.9±6.4 0.258
Stent diameter, mm   3.4±0.4   3.4±0.4 0.980
Stent length, mm 19.1±4.1 18.0±4.1 0.329
Stent type 0.099
    SES (Cypher) 17 (39.5%)   5 (19.2%)
    PES (Taxus) 1 (2.3%) 0 (0%)
    ZES (Endeavor Sprint) 23 (53.5%) 16 (61.5%)
    ZES (Endeavor Resolute) 2 (4.7%)   5 (19.2%)
LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, 
zotarolimus-eluting stent. Young-Guk Ko, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 3   May 2012 512
DISCUSSION
The major findings of the present study are as follows: 1) 
The relative content of necrotic core tended to be higher 
and the relative content of fibro-fatty tissue tended to be 
lower in patients with unstable angina than in patients with 
stable angina. 2) Pre- and post-PCI blood levels of bio-
markers such as hsCRP, sCD40L, MMP-9, and neopterin 
only pre-PCI blood level of neopterin showed a mildly sig-
nificant correlation with the absolute volume of the necrotic 
core in the target lesion (r=0.320, p=0.008). Pre- and post-
PCI blood levels of sCD40L (r=0.220, p=0.072; r=0.231, 
p=0.062) and post-PCI blood level of neopterin (r=0.238, 
p=0.051) also showed trends toward positive correlation 
with the absolute volume of necrotic core in the target le-
sion. However, other biomarker levels were not correlated 
with relative or absolute content of necrotic core. 
Table 4. Pre- and Postprocedural Blood Levels of Biomarkers
Biomarker Stable angina (n=44) Unstable angina (n=26) p value
hsCRP (mg/L)
    Pre-PCI  0.7±0.7 1.2±1.3 0.148
    Post-PCI at 24 hrs  2.0±2.2 2.7±2.1 0.203
    Δ  1.2±1.9 1.5±1.7 0.490
Soluble CD40 ligand (ng/mL)
    Pre-PCI 2.6±2.3 2.0±2.6 0.376
    Post-PCI at 24 hrs 2.6±3.0 3.4±3.1 0.299
    Δ -0.1±0.3 2.9±0.8 0.043
MMP-9 (μg/L)
   Pre-PCI 303.1±112.3 359.3±190.9 0.189
   Post-PCI at 24 hrs 826.9±258.7 799.0±282.8 0.691
   Δ 505.5±256.4 451.0±214.7 0.390
Neopterin (nmol/L) 
   Pre-PCI 5.1±2.7 5.5±3.4 0.543
   Post-PCI at 24 hrs 6.5±3.1 6.4±3.3 0.580
   Δ 1.4±1.5 0.8±0.9 0.087
hsCRP, high sensitivity C-reactive protein; PCI, percutaneous coronary intervention; MMP, matrix metalloproteinase.
Table 3. Preprocedural Intravascular Ultrasound and Virtual Histology Data for the Target Lesions 
Stable angina (n=44) Unstable angina (n=26) p value
Target lesion CSA with minimum lumen area 
    EEM CSA, mm
2 14.0±4.0 14.3±3.9 0.754
    Lumen CSA, mm
2   2.5±0.6   2.7±0.9 0.323
    P&M CSA, mm
2 11.5±3.9 11.7±3.8 0.891
    Plaque burden, % 81.3±5.5 80.4±6.5 0.557
    Fibrous CSA, %   67.2±13.2   65.2±14.5 0.555
    Fibrofatty CSA, % 10.2±5.5   8.3±4.2 0.126
    NC CSA, % 14.3±9.8 15.4±8.5 0.631
    DC CSA, %   8.3±7.3   11.1±10.4 0.186
    Remodeling index   0.98±0.09   1.10±0.07 <0.001
Whole target lesion volume 
    EEM volume, mm
3 257.8±92.3 249.1±88.4 0.701
    Lumen volume, mm
3   98.9±36.3   95.7±36.1 0.723
    P&M volume, mm
3 158.8±65.5 153.3±63.9 0.735
    Plaque burden, % 61.3±7.9 60.9±8.7 0.853
    Fibrous volume, %   65.3±10.8   62.4±12.2 0.313
    Fibrofatty volume, %   9.4±3.8   7.5±3.7 0.052
    NC volume, % 15.1±8.1 18.3±7.6 0.110
    DC volume, %   9.4±6.5 11.4±7.2 0.226
CSA, cross sectional area; EEM, external elastic membrane; P&M, plaque and media; NC, necrotic core; DC, dense calcium.Necrotic Core by VH and Biomarkers 
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Inflammation plays a key role in atherosclerosis and 
plaque vulnerability. CRP is a liver-derived acute phase pro-
tein involved in innate immune response.18 CRP has been 
found to induce the expression of adhesion molecules, such 
as Vascular Cell Adhesion Molecule-1, Inter-Cellular Adhe-
sion Molecule-1 and E-selectin, as well as monocyte chemo-
attractant factor-1.19,20 CRP also increases tissue factor ex-
pression in monocyte-macrophages; promotes monocyte 
chemotaxis and adhesion to endothelial cells; stimulates the 
release of reactive oxygen species and MMP-1; and pro-
did not differ between the SA group and the UA group. 
However, the increase in the blood level of sCD40L after 
PCI was significantly higher in UA patients than in SA pa-
tients. 3) Among the various biomarkers evaluated, only 
pre-PCI blood level of neopterin showed a weakly signifi-
cant correlation with the absolute volume of the necrotic 
core in the target lesion. Pre- and post-PCI blood levels of 
sCD40L and post-PCI blood level of neopterin also showed 
trends toward a positive correlation with the absolute vol-
ume of necrotic core in the target lesion. 
Table 5. Correlations of Necrotic Core Contents Determined by Virtual Histology with Periprocedural Blood Levels of Bio-
markers
Necrotic core content  Biomarkers  r p value
Relative content of necrotic core at 
  the cross section with minimum 
  lumen area
hsCRP (pre-PCI) 0.088 0.474
hsCRP (post-PCI 24 hrs) 0.081 0.513
hsCRP (Δ) 0.067 0.590
sCD40L (pre-PCI) 0.170 0.165
sCD40L (post-PCI 24 hrs) 0.172 0.168
sCD40L (Δ) -0.016 0.894
MMP-9 (pre-PCI) 0.173 0.165
MMP-9 (post-PCI 24 hrs) 0.077 0.546
MMP-9 (Δ) 0.033 0.794
Neopterin (pre-PCI) 0.097 0.433
Neopterin (post-PCI 24 hrs) 0.032 0.797
Neopterin (Δ) -0.140 0.255
Relative content of necrotic core in 
  the target lesion volume
hsCRP (pre-PCI) 0.109 0.376
hsCRP (post-PCI 24 hrs) 0.125 0.314
hsCRP (Δ) 0.093 0.453
sCD40L (pre-PCI) 0.179 0.166
sCD40L (post-PCI 24 hrs) 0.234 0.058
sCD40L (Δ) -0.043 0.726
MMP-9 (pre-PCI) 0.161 0.197
MMP-9 (post-PCI 24 hrs) 0.112 0.382
MMP-9 (Δ) 0.024 0.853
Neopterin (pre-PCI) 0.155 0.207
Neopterin (post-PCI 24 hrs) 0.071 0.567
Neopterin (Δ) -0.178 0.147
Absolute necrotic core volume in the 
  target lesion
hsCRP (pre-PCI) 0.086 0.486
hsCRP (post-PCI 24 hrs) 0.152 0.221
hsCRP (Δ) 0.149 0.224
sCD40L (pre-PCI) 0.220 0.072
sCD40L (post-PCI 24 hrs) 0.231 0.062
sCD40L (Δ) -0.060 0.629
MMP-9 (pre-PCI) 0.155 0.213
MMP-9 (post-PCI 24 hrs) 0.025 0.844
MMP-9 (Δ) -0.022 0.861
Neopterin (pre-PCI) 0.320 0.008
Neopterin (post-PCI 24 hrs) 0.238 0.051
Neopterin (Δ) -0.153 0.214
hsCRP, high sensitivity C-reactive protein; PCI, percutaneous coronary intervention; sCD40L, soluble CD40 ligand; MMP, matrix metalloproteinase.Young-Guk Ko, et al.
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coronary stenting was significantly higher in UA patients 
than in SA patients. Previous studies have shown that blood 
levels of inflammatory biomarker rise after PCI possibly due 
to vascular and myocardial injury related to the proce-
dure.37,38 Kozinski, et al.39 also reported that the rise in the 
serum levels of hsCRP and serum amyloid A after coronary 
intervention was greater for UA compared with SA. Al-
though the clinical implication of elevated inflammatory 
biomarkers after coronary stenting is not fully clarified, a 
correlation between the levels of CRP after coronary stent-
ing and the cardiovascular event rate during follow-up has 
been suggested.37,40 
There are several potential explanations for weak or poor 
correlations between the biomarker levels and the relative 
content of necrotic core by VH in our study. First, our study 
sample may have been too small to detect any significant 
relationships between tissue composition analyzed by VH 
and blood biomarker levels. Second, the blood levels of bio-
markers generally represent systemic inflammation and 
may not reflect local inflammation status or tissue charac-
teristics of PCI target lesions. For instance, we cannot rule 
out the possibility that the blood level of biomarkers may 
have been more affected by non-PCI target lesion with mild-
to-moderate plaque burden and/or non-coronary atheroscle-
rotic lesions than by the PCI target lesions. Furthermore, 
non-vascular origins of inflammation may have been re-
sponsible for the status of systemic inflammation, although 
we excluded patients with known infectious or inflammato-
ry disease. Third, potential impact of previous use of statin 
on the results of the present study cannot be ruled out. Statins 
are known to reduce blood levels of inflammatory biomark-
ers and to exert effects on vascular remodeling and plaque 
composition.41,42 However, whether statins had different de-
gree of influence on blood levels of biomarkers and tissue 
composition of target lesions in our study cannot be clari-
fied within the limits of the present study. Fourth, tissue 
characterization by VH may not be sufficient. VH valida-
tion studies on human coronary arteries ex vivo have fo-
cused solely on the detection of particular tissue types in 
limited regions of interest. However, VH has never been 
validated for determination of the absolute or relative areas 
of any particular tissue component in human coronary ar-
teries. Recently, Thim, et al.43 reported that the necrotic 
cores of minipig coronary artery plaques assessed by VH 
did not correlate with pathologic findings, especially when 
calcifications in the necrotic core were not present or not 
detected. Therefore, VH may require more pathologic vali-
motes oxidized low-density lipoprotein uptake, which re-
sults in increased foam cell formation.21 Recently, several 
studies discovered CRP in coronary and carotid athero-
ma.22,23 However, a question of whether CRP directly con-
tributes to atherogenesis is still controversial. Activated 
platelets express CD40 ligand, which is then cleaved and 
released as sCD40L.24 The sCD40L binds to circulating 
monocytes through both its receptor, CD40, and through 
the monocyte/macrophage integrin Mac-1, and this binding 
promotes monocyte adhesion to the vascular endothelium.25 
The sCD40L also binds to CD40 on endothelial cell surfac-
es, which activates the expression of adhesion molecules on 
endothelial cell surfaces.26 MMPs are a family of more than 
20 zinc-containing endoproteinases that contribute to colla-
gen degradation and weakening of the fibrous cap.27 In-
creased expressions of MMP-1, -3 and -9 have been found 
at the rupture prone shoulder regions of atherosclerotic 
plaques.28 Neopterin is also produced by activated macro-
phages and is thought to be a marker of immune activation 
and macrophage activity.29 Neopterin can act as a pro-oxi-
dant, enhancing oxidant production and promoting cell 
death or atherosclerotic plaque instability.29 Avanzas, et al.30 
reported that serum neopterin is an independent predictor of 
major adverse coronary events in patients with chronic sta-
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In conclusion, we found a weak correlation between the 
pre-PCI neopterin level and necrotic core volume in the 
PCI-target lesion. The clinical implications of our findings 
need to be investigated in further studies.  
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